clobazam / Generic mfg. - LARVOL DELTA

Solute Carrier 45A1: A New Cerebral Glucose Transporter Brain Disorder with Focal Refractory Epilepsy Responsive to Ketogenic Diet and Acetazolamide. (PubMed, Neuropediatrics) - "The patient was treated unsuccessfully with carbamazepine, valproate, levetiracetam, lamotrigine, topiramate, lacosamide, and clobazam. Acetazolamide was introduced with seizure freedom for 10 months. Exome analysis revealed compound heterozygous variants p.Pro560Leu and p.Arg57Cys in the SLC45A1 gene.This case illustrates that KD and acetazolamide might be effective in SLC45A1-related epilepsy and underscores the importance of genetic testing in the presurgical evaluation of epilepsy."

Journal • CNS Disorders • Developmental Disorders • Epilepsy • Mental Retardation

A precision approach to therapeutic drug monitoring of valproate to evaluate markers of toxicity. (PubMed, Epilepsia) - "Combined use of TDM including total and unbound VPA serum concentrations and biochemical analyses of ammonia and liver enzymes are useful as tailored precision monitoring to aid clinical decision-making in patients with suspected symptoms of toxicity."

Journal • CNS Disorders • Epilepsy

Cenobamate for Adjunctive Treatment in Adult and Pediatric Patients with Refractory Lennox-Gastaut Syndrome: A Retrospective Chart Review. (PubMed, Neurol Ther) - "This chart review provides promising evidence for the efficacy of CNB in treating LGS. Additional prospective studies will help to clarify CNB's efficacy and safety profile for patients with LGS."

Journal • Retrospective data • CNS Disorders • Epilepsy • Pediatrics

Effects of antiseizure drugs zonisamide, oxcarbazepine, clobazam, and lacosamide on FOXO1, LIF, and E-cadherin- mediated molecules in rat embryo implantation. (PubMed, Life Sci) - "These results suggest that long-term administration of ZNS, OXC, CLB, and LCM may impair implantation by altering key molecular markers. The findings highlight potential reproductive risks associated with chronic antiepileptic drug exposure during adolescence."

Journal • Preclinical • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia • Oncology • CDH1 • FOXO1 • LIF

A model-based cohort study of clobazam exposure and clinical efficacy and safety in children with drug-resistant epilepsy (ChiCTR) - P4 | N=100 | Recruiting | Sponsor: Children’s Hospital of Soochow University; Children’s Hospital of Soochow University

New P4 trial • CNS Disorders • Epilepsy

Current and emerging pharmacotherapies in lennox-Gastaut syndrome. (PubMed, Expert Opin Pharmacother) - "This review examines FDA-approved medications for LGS (clonazepam, felbamate, lamotrigine, topiramate, rufinamide, clobazam, cannabidiol, and fenfluramine), commonly used off-label antiseizure medications, emerging treatments in clinical trials, and precision therapeutics targeting etiology-specific mechanisms. Future progress depends on improved natural history studies, standardized data collection, advanced preclinical models, innovative trial designs, and addressing healthcare inequities. While emerging precision therapies targeting genetic causes show promise, the field urgently needs better strategies to optimize existing treatments while developing disease-modifying approaches that address both seizures and non-seizure outcomes."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Gene Therapies

Clobazam as an add-on treatment for medically refractory brain tumor-related epilepsy. (ASCO 2025) - "This data suggests that clobazam is an effective add on medication for patients with medically refractory tumoral epilepsy. Furthermore, the data strongly suggests that if patients are going to respond to clobazam, a response is typically seen within 6 months, which can help guide clinical decision making for patients starting clobazam. An improvement in seizure burden is a clear goal for patients with BTRE, although the ability to wean concurrent agents is similarly an essential goal of treatment."

Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • CNS Disorders • Epilepsy • Fatigue • Glioblastoma • Glioma • Oligodendroglioma • Oncology • Pain • Solid Tumor

The Impact of Puberty on Children With GLUT1 Deficiency Syndrome. (PubMed, Pediatr Neurol) - "Puberty in GLUT1DS was most likely to worsen movement disorders, but about one third also had increased seizures and the onset of migraines and mood swings. For those on a ketogenic diet, although ketosis often decreases, this was not uniformly associated with more seizures."

Journal • CNS Disorders • Epilepsy • Migraine • Movement Disorders • Pain • SLC2A1

Status Epilepticus in Melas; Will There Ever Be a Solution? (ATS 2025) - "Unable to control her seizures with high-dose lorazepam and the addition of oral clobazam, she was transferred to the neurosurgical intensive care unit (ICU), intubated, and started on a continuous midazolam infusion for aggressive seizure control...Our patient achieved 24 hours of seizure-free activity by adding the aforementioned benzodiazepines to her home regimen of levetiracetam, lamotrigine, L-arginine, levocarnitine, cyproheptadine, niacin, riboflavin, coenzyme Q10, and thiamine. Unfortunately, attempts to wean midazolam infusion failed as seizure activity recurred despite the addition of perampanel to her antiepileptic regimen...It is worth wondering whether status epilepticus could have been avoided if her VNS had been active. Unfortunately, given the complexity, mortality remains high with reported mean survival only into the third decade of life."

Cardiovascular • Epilepsy • Genetic Disorders • Metabolic Disorders • Movement Disorders

Cenobamate in Real-Word Scenario: Results on Efficacy, Side Effects, and Retention Rate in a Single Center Retrospective Study. (PubMed, Brain Behav) - "In this large cohort of 262 PWE, CNB proved very efficient with a high retention rate over one year. Co-medication with perampanel or GABA receptor modulators was linked to seizure-freedom. The overall positive impression of CNB is further supported."

Adverse events • Journal • Retrospective data • CNS Disorders • Epilepsy

Caregiver-reported non-seizure and seizure outcomes with cannabidiol and clobazam in patients aged ≥2 years with Lennox-Gastaut syndrome or Dravet syndrome: A subgroup analysis of the BECOME survey. (PubMed, Seizure) - "Consistent with the overall BECOME survey, most caregivers of patients with LGS/DS aged ≥2 years taking concomitant clobazam reported improvements in seizure and non-seizure outcomes since initiating CBD treatment."

Journal • CNS Disorders • Epilepsy

Efficacy of Stiripentol Beyond Dravet Syndrome: A Retrospective Medical Record Review of Patients with Drug-Resistant Epilepsies. (PubMed, Neurol Ther) - "Add-on stiripentol provides overall improvement in different seizure types and non-seizure manifestations for paediatric patients with drug-resistant epilepsy, including epileptic syndromes besides DS, and appeared effective in acute treatment of SE. Stiripentol was generally well tolerated."

Journal • Retrospective data • CNS Disorders • Epilepsy • Pediatrics

Cannabidiol metabolism in vitro: the role of antiseizure medications and CYP2C19 genotypes. (PubMed, Xenobiotica) - "CBD depletion in pooled human liver microsomes was studied at varying concentrations (400-6000 nM) in the absence and presence of valproic acid, clobazam, stiripentol and topiramate. Projected decreases in CBD CLint values when combined with several antiseizure medications simultaneously suggest a possibility drug-drug interaction potential to clinical relevance. A 1.3- to 4.8-fold increased exposure to unbound systemic CBD concentrations was predicted when combined with these antiseizure medications."

Journal • Preclinical • CNS Disorders • Epilepsy • CYP2C19

European experience of steroid therapy in children with developmental and epileptic encephalopathy with spike wave activation in sleep ((D)EE-SWAS). (PubMed, Orphanet J Rare Dis) - "Steroids are part of the first line therapy of (D)EE-SWAS across Europe, but heterogeneity in formulations, dosages, and regimens persists due to limited guideline availability. The absence of comparative studies and the discordant definitions of (D)EE-SWAS further hinder comparisons of treatment efficacy. We recommend that harmonizing steroid treatment strategies is imperative for optimizing (D)EE-SWAS management."

Journal • CNS Disorders • Epilepsy

Clinical characteristics of neonatal seizures and post-neonatal epilepsy in children with trisomy 18 (PAS 2025) - "Despite treatment with phenobarbital and perampanel in four patients, levetiracetam in three, clobazam in two, and valproic acid and topiramate in one, all patients continued to experience seizures. Neonatal seizures occurred in 8 of the 27 patients. Table 1 presents the treatment regimens and seizure types. Eight patients experienced seizure resolution during the neonatal period."

Clinical • Cardiovascular • CNS Disorders • Epilepsy

The Amorphous State of the Antiepileptic Clobazam: Preparation and Characterization. (PubMed, AAPS PharmSciTech) - "In conclusion, amorphous CLOB was successfully prepared in the laboratory for the first time and thoroughly characterized. It easily devitrified to CLOB-c by effect of different stressors, and thus it could not have advantages over CLOB-c in terms of physical stability."

Journal

Pharmaceutical pollution influences river-to-sea migration in Atlantic salmon (Salmo salar). (PubMed, Science) - "We argue that such effects may arise from altered shoaling behavior in fish exposed to clobazam. Drug-induced behavioral changes are expected to have wide-ranging consequences for the ecology and evolution of wild populations."

Journal

Unraveling Infantile Epileptic Spasms in the Context of Primary Mitochondrial Disease (P2-6.004). (PubMed, Neurology) - "Treatment strategies included ACTH, Vigabatrin, prednisone, Topamax, Clobazam, Epidiolex, Keppra and Ketogenic diet, leading to resolution of spasms in 8 patients (57%) within 1 to 24 months. Catenaccio has received research support from NIH. Amy Goldstein has received personal compensation in the range of $500-$4,999 for serving as a speaker with UMDF."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Metabolic Disorders • Pediatrics • PDHA1

A Case of Aicardi Syndrome with Positive Outcomes Following Hemispherectomy (P10-9.015). (PubMed, Neurology) - "EEG showed hypsarrhythmia responsive to vigabatrin...Patient trialed on carbamazepine, oxcarbazepine, divalproex, levetiracetam, phenobarbital, phenytoin, clobazam, and topiramate...Medication regimen consisted of oxcarbazepine 900 mg BID, brivaracetam 150 mg BID, cenobamate 200 mg daily, and cannabidiol 2 mL/kg BID...In light of dramatic improvement in seizure frequency and severity, she weaned off multiple antiepileptic medications, now on cenobamate 300 mg and klonopin 0.5 mg daily...Dr. Proteasa has nothing to disclose."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Genetic Disorders • Rare Diseases

Characterization of a unique patient cohort with spike-wave activation in sleep without cognitive decline or increased seizure burden: Considerations for a more conservative treatment approach. (PubMed, Seizure) - "This study suggests that if patients have "isolated-SWAS" at the time of diagnosis a more conservation approach may be considered."

Journal • CNS Disorders • Epilepsy

Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: A multicenter real-world study. (PubMed, Epilepsia) - "This study supports CBD as a potential treatment for monogenic epilepsies beyond its licensed indications, demonstrating comparable effectiveness between approved and off-label use and suggesting genetic subgroups with promising treatment responses."

Clinical • Journal • Real-world evidence • CNS Disorders • Developmental Disorders • Epilepsy • Mental Retardation • TSC2

Clinical signatures of SYNGAP1-related disorders through data integration. (PubMed, Genet Med) - "We delineated the seizure, developmental, and behavioral trajectories in SYNGAP1-related disorders, to improve diagnosis, prognosis, and clinical care, as well as facilitating clinical trial readiness."

Journal • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Mental Retardation • Psychiatry

Efficacy and safety of pharmacological and non-pharmacological therapies in Lennox-Gastaut syndrome: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "The treatments assessed included cannabidiol, fenfluramine, clobazam, rufinamide, felbamate, lamotrigine, topiramate, deep brain stimulation, and anterior corpus callosotomy. Clobazam 1 mg/kg/day, anterior corpus callosotomy, and rufinamide manifested the most optimal efficacy in seizure control among LGS patients. Caution should be exercised when administering cannabidiol, lamotrigine, and fenfluramine 0.7 mg/kg/day in clinical practice to mitigate safety concerns associated with drug-related side effects."

Journal • Retrospective data • Review • CNS Disorders • Epilepsy

Real-world experience of cannabidiol in conjunction with clobazam for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: Results from a retrospective multicentre chart review in Germany. (PubMed, Epilepsy Behav) - "In this chart review of patients with severe treatment refractory LGS or DS receiving adjunctive CBD and CLB concomitantly, a reduction in seizure frequency and sustained treatment retention was observed for up to 12 months across age groups in real-world clinical practice. CBD discontinuations exclusively due to AEs were infrequent and the AE profile was generally aligned to that previously observed."

Journal • Real-world evidence • Retrospective data • Anesthesia • CNS Disorders • Epilepsy • Pediatrics

Group D Salmonella Meningitis in the Neonate (AAN 2025) - "Blood and CSF cultures grew Salmonella group D of presumed vertical transmission at birth and patient was initiated on a protracted course of ceftazidime...Seizures were refractory to initial treatment of phenobarbital, fosphenytoin, levetiracetam and midazolam infusion requiring escalation of treatment to include lacosamide, clobazam, and ultimately ketamine infusion for secondary neuroprotection...NTS meningitis, is a rare yet severe CNS infection with a high mortality rate, and potential for multiple neurologic complications. Early diagnosis and proactive neuromonitoring in the form of continuous EEG and sequential neuroimaging are essential for prompt treatment to optimize outcomes through secondary injury prevention."

CNS Disorders • Epilepsy • Hematological Disorders • Hepatology • Infectious Disease • Movement Disorders • Respiratory Diseases • Ventriculomegaly